The observation that semaglutide use was associated with lower risks of cognitive deficits and, to some extent, dementia than the DPP4I sitagliptin and the sulphonylurea glipizide, but a similar risk compared to the SGLT2I empagliflozin aligns with a recent network meta-analysis showing that SGLT2Is and GLP1-RAs rank better than DPP4Is and sulphonylureas in terms of cognitive outcomes and dementia.17 Here, GLP1R is linked to dementia.